[1]Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern\[J\]. Lancet, 2020, 395(10223): 470-473.
[2]Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirusinfected pneumonia\[J\]. N Engl J Med, 2020, 382(13): 1199-1207.
[3]Carlos WG, Dela Cruz CS, Cao B, et al. Novel Wuhan (2019nCoV)coronavirus\[J\]. Am J Respir Crit Care Med, 2020, 201(4): P7-P8.
[4]Huang C, Wang Y, Li X,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China\[J\]. Lancet, 2020, 395(10223): 497-506.
[5]Woo PC, Lau SK, Huang Y, et al. Coronavirus diversity, phylogeny and interspecies jumping\[J\]. Exp Biol Med(Maywood), 2009, 234(10): 1117-1127.
[6]Perlman S, Netland J. Coronaviruses postSARS:update on replication and pathogenesis\[J\]. Nat Rev Microbiol, 2009, 7(6): 439-450.
[7]Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses\[J\]. Nat Rev Microbiol, 2019, 17(3): 181-192.
[8]Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China:a descriptive study\[J\]. Lancet, 2020, 395(10223): 507-513.
[9]Ren LL, Wang YM, Wu ZQ, et al.Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study\[J\]. Chin Med J (Engl), 2020. doi: 10.1097/CM9.0000000000000722.[Epub ahead of print]
[10]Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019\[J\]. N Engl J Med, 2020, 382(8): 727-733.
[11]国家卫生健康委办公厅.新型冠状病毒肺炎诊疗方案(试行第七版)\[EB/OL\].(2020-03-03)\[2020-03-10\]. http:∥www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.
[12]Tian X, Li C, Huang A, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirusspecific human monoclonal antibody\[J\]. Emerg Microbes Infect, 2020, 9(1): 382-385.
[13]Tang X, Wu C, Li X, et al. On the origin and continuing evolution of SARSCoV2\[J\]. Natl Sci Rev, 2020. doi: 10.1093/nsr/nwaa036.[Epub ahead of print]
[14]Dong N,Yang X, Ye L, et al. Genomic and protein structure modelling analysis depicts the origin and infectivity of 2019nCoV, a new coronavirus which caused a pneumonia outbreak in Wuhan,China\[J\]. bioRxiv, 2020. doi: 10.1101/2020.01.20.913368.[Epub ahead of print]
[15]Li F. Receptor recognition and crossspecies infections of SARS coronavirus\[J\]. Antiviral Research, 2013, 100(1): 246-254.
[16]Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission\[J\]. Sci China Life Sci, 2020, 63(3): 457-460.
[17]Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARSCoV2 and other lineage B betacoronaviruses\[J\]. Nat Microbiol, 2020, 5(4): 562-569.
[18]Zhang H, Kang Z, Gong H, et al. The digestive system is a potential route of 2019nCov infection: a bioinformatics analysis based on singlecell transcriptomes\[J\]. bioRxiv, 2020. doi: 10.1101/2020.01.30.927806.[Epub ahead of print]
[19]Tao Y, Shi M, Chommanard C, et al. Surveillance of bat coronaviruses in kenya identifies relatives of human coronaviruses NL63 and 229E and their recombination history\[J\]. J Virol, 2017, 91(5): e01953.
[20]Hui DS, I Azhar E, Madani TA, et al. The continuing 2019nCoV epidemic threat of novel coronaviruses to global health The latest 2019 novel coronavirus outbreak in Wuhan, China\[J\]. Int J Infect Dis, 2020, 91: 264-266.
[21]Ji W, Wang W, Zhao X, et al. Crossspecies transmission of the newly identified coronavirus 2019nCoV\[J\]. J Med Virol, 2020, 92(4): 433-440.
[22]Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin\[J\]. Nature, 2020, 579(7798): 270-273.
[23]Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding\[J\]. Lancet, 2020, 395(10224): 565-574.
[24]Lam TT, Shum MH, Zhu H, et al. Identification of 2019nCoV related coronaviruses inmalayan pangolins in southern China\[J\]. bioRxiv, 2020. doi: 10.1101/2020.02.13.945485.[Epub ahead of print]
[25]Paules CI, Marston HD, Fauci AS. Coronavirus infections—more than just the common cold\[J\]. JAMA, 2020, 323(8): 707-708.
[26]Guan W, Ni Z, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China\[J\].medRxiv, 2020. doi:10.1101/2020.02.06.20020974.[Epub ahead of print]
[27]Yu WB, Tang GD, Zhang L, et al. Decoding the evolution and transmissions of the novel pneumonia coronavirus (SARSCoV2) using whole genomic data\[J\]. ChinaXiv, 2020, 02, 00033v2.
[28]Chan JF, Yuan S, Kok K, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating persontoperson transmission:a study of a family cluster\[J\]. Lancet, 2020, 395(10223): 514-523.
[29]Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019nCoVinfection from an asymptomatic contact in germany\[J\]. N Engl J Med, 2020, 382(10): 970-971.
[30]Wang W, Xu Y, Gao R, et al. Detection of SARSCoV2 indifferent types of clinical specimens\[J\]. JAMA, 2020. doi: 10.1001/jama.2020.3786.[Epub ahead of print]
[31]Zhang W, Du R, Li B, et al. Molecular and serological investigation of 2019nCoV infected patients:implication of multiple shedding routes\[J\]. Emerg Microbes Infect, 2020, 9(1): 386-389.
[32]Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusinfected pneumonia in Wuhan,China\[J\]. JAMA, 2020, 323(11): 1061-1069.
[33]Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERSCoV):a systematic review and metaanalysis\[J\]. Int J Infect Dis, 2016, 49: 129-133.
[34]Channappanavar R, Fett C, Mack M, et al. Sexbased differences in susceptibility to Severe Acute Respiratory Syndrome Coronavirus infection\[J\]. J Immunol, 2017, 198: 4046-4053.
[35]Wang XF, Shi GC,Wan HY, et al. Clinical features of three avian influenza H7N9 virusinfected patients in Shanghai\[J\]. Clin Respir J, 2014, 8(4): 410-416.
[36]Zhao S, Lin Q, Ran J, et al. Preliminary estimation of the basic reproduction number of novel coronavirus (2019nCoV) in China,from 2019 to 2020: A datadriven analysis in the early phase of the outbreak\[J\]. Int J Infect Dis, 2020, 92: 214-217.
[37]Bauch CT, LloydSmith JO, Coffee MP, et al. Dynamicallymodeling SARS and other newly emerging respiratory illnesses: past,present,and future\[J\]. Epidemiology, 2005, 16(6): 791-801.
[38]Wallinga J, Teunis P. Different epidemic curves for severe acute respiratory syndrome reveal similar impacts of control measures\[J\]. Am J Epidemiol, 2004, 160(6): 509-516.
[39]Lin Q, Chiu AP, Zhao S, et al. Modeling the spread of Middle East respiratory syndrome coronavirus in Saudi Arabia\[J\]. Stat Methods Med Res, 2018, 27(7): 1968-1978.
[40]Kui L, Fang Y, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province\[J\]. Chin Med J (Engl), 2020. doi: 10.1097/cm9.0000000000000744.[Epub ahead of print]
[41]Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARSCoV2 in Wuhan,China\[J\]. Allergy, 2020. doi:10.1111/all.14238.[Epub ahead of print]
[42]Memish ZA, AlTawfiq JA, Makhdoom HQ, et al. Respiratorytract samples,viral load,and genome fraction yield in patients with Middle East Respiratory Syndrome\[J\]. Int J Infect Dis, 2014, 210(10): 1590-1594.
[43]Assiri A, AlTawfiq JA, AlRabeeah AA, et al. Epidemiological,demographic,and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia:a descriptive study\[J\]. Lancet Infect Dis, 2013, 13(9): 752-761.
[44]Rahman A, Sarkar A. Riskfactors for fatal Middle East Respiratory Syndrome Coronavirus infections in Saudi Arabia:analysis of the WHO line list,2013—2018\[J\]. Am J Public Health, 2019, 109(9): 1288-1293.
[45]Fang Y, Zhang H, Xie J, et al. Sensitivity ofchest CT for COVID19:comparison to RTPCR\[J\]. Radiology, 2020: 200432.
[46]Xie X, Zhong Z, Zhao W, et al. Chest CT fortypical 2019nCoV pneumonia:relationship to negative RTPCR testing\[J\]. Radiology, 2020: 200343.
[47]Pan F, Ye T, Sun P, et al. Timecourse of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID19) pneumonia\[J\]. Radiology, 2020: 200370.
[48]Ling Z, Xu X, Gan Q, et al. Asymptomatic SARSCoV2 infected patients with persistent negative CT findings\[J\]. Eur J Radiol, 2020, 126:108956.
[49]Lai CC, Shih TP, Ko WC, et al. Severe acute respiratory syndrome coronavirus 2 (SARSCoV2) and coronavirus disease2019 (COVID19):the epidemic and the challenges\[J\]. Int J Antimicrob Agents, 2020: 105924.
[50]Bernheim A, Mei X, Huang M, et al. Chest CT findings in coronavirus disease19 (COVID19):relationship to duration of infection\[J\]. Radiology, 2020:200463.
[51]Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARSCoV2) outside of Wuhan,China:retrospective case series\[J\]. BMJ, 2020, 368: m606.
[52]Wu F, Zhao S, Yu B, et al. Complete genome characterisation of a novel coronavirus associated with severe human respiratory disease in Wuhan,China\[J\].bioRxiv, 2020. doi:10.1101/2020.01.24.919183.[Epub ahead of print]
[53]Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia\[J\]. J Thromb Haemost, 2020, doi: 10.1111/jth.14768.[Epub ahead of print]
[54]Wang N, Li SY, Yang XL, et al. Serological evidence of bat SARSrelated coronavirus infection in humans,China\[J\]. Virol Sin, 2018, 33(1): 104-107.
[55]Xiao SY, Wu Y, Liu H. Evolving status of the 2019 novel coronavirus infection:proposal of conventional serologic assays for disease diagnosis and infection monitoring\[J\]. J Med Virol, 2020. doi: 10.1002/jmv.25702.[Epub ahead of print]
[56]Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings\[J\]. Thorax, 2004, 59(3): 252-256.
[57]Nukoolkarn V, Lee V S, Malaisree M, et al. Molecular dynamic simulations analysis of ritronavir and lopinavir as SARSCoV 3CLpro inhibitors\[J\]. J Theor Biol, 2008, 254(4): 861 -867.
[58]Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings\[J\]. Thorax, 2004, 59(3): 252-256.
[59]Cao B, Wang Y, Wen D, et al. Atrial of lopinavirritonavir in adults hospitalized with severe Covid19\[J\]. N Engl J Med, 2020. doi: 10.1056/NEJMoa2001282.[Epub ahead of print]
[60]Glowacka I, Bertram S, Müller MA, et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response\[J\]. J Virol, 2011, 85(9): 4122-4134.
[61]Shulla A, HealdSargent T, Subramanya G,et al. A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry\[J\]. J Virol, 2011, 85(2): 873-882.
[62]Markus H, Hannah K, Nadine K, et al. The novel coronavirus 2019 (2019nCoV) uses the SARScoronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells\[J\]. bioRxiv, 2020. doi: 10.1101/2020.01.31.929042.[Epub ahead of print]
[63]Li Y, Zhang JY, Wang N, et al. Therapeutic drugs targeting 2019nCoV main protease by highthroughput screening\[J\]. bioRxiv, 2020. doi: 10.1101/2020.01.28.922922.[Epub ahead of print]
[64]De Clercq E, Li G. Approved antiviral drugs over the past 50 years\[J\]. Clin Microbiol Rev, 2016, 29: 695-747.
[65]Warren TK, Wells J, Panchal RG, et al. Protection against filovirus diseases by a novel broadspectrum nucleoside analogue BCX4430\[J\]. Nature, 2014, 508(7496): 402-405.
[66]Colson P, Rolain JM, Raoult D. Chloroquine for the 2019 novel coronavirus SARSCoV2\[J\]. Int J Antimicrob Agents, 2020, 55(3): 105923.
[67]Yan Y, Zou Z, Sun Y, et al. Antimalaria drug chloroquine is highly effective in treating avian influenza a H5N1 virus infection in an animal model\[J\]. Cell Res, 2013, 23(2): 300-302.
[68]Gao JJ, Tian ZX, Yang X. Breakthrough:chloroquine phosphate has shown apparent efficacy in treatment of COVID19 associated pneumonia in clinical studies\[J\]. Biosci Trends, 2020. doi:10.5582/bst.2020.01047.[Epub ahead of print]
[69]Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019nCoV) in vitro\[J\]. Cell Res, 2020, 30(3): 269-271.
[70]Lansbury L, Rodrigo C, LeonardiBee J, et al. Corticosteroids as adjunctive therapy in the treatment of influenza\[J\]. Cochrane Database Syst Rev, 2019, (2): CD010406.
[71]Chen F, Chan KH, Jiang Y, et al.In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds\[J\]. J Clin Virol, 2004, 31(1): 69-75.
[72]Lu H. Drug treatment options for the 2019new coronavirus (2019nCoV)\[J\].Biosci Trends, 2020. doi: 10.5582/bst.2020.01020.[Epub ahead of print]
[73]Luo H, Tang QL, Shang YX, et al.Can Chinese medicine be used for prevention of Corona Virus Disease 2019 (COVID19)? a review of historical classics,research evidence and current prevention programs\[J\]. Chin J Integr Med, 2020. doi: 10.1007/s11655-020-3192-6.[Epub ahead of print]
|